Basic Information
Litfulo
Regulatory Information
EMEA/H/C/006025
Authorised
September 15, 2023
July 20, 2023
5
October 14, 2024
Company Information
Belgium
Boulevard de la Plaine 17 1050 Bruxelles
Pfizer Europe MA EEIG
Drug Classification
Additional Monitoring
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
Overview Summary
Litfulo is a medicine used to treat adults and adolescents over 12 years of age with severe alopecia areata, an autoimmune disease (a disease caused by the body’s own defence system attacking normal tissue) causing hair loss of the scalp or other parts of the body. Litfulo contains the active substance ritlecitinib.